SOLENO THERAPEUTICS INC
SLNONasdaqHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $190.4M | — | — | — | — | — |
| Operating income | $9.4M | −$187.7M | −$41.4M | −$24.4M | −$31.5M | −$36.3M |
| Net income | $20.9M | −$175.8M | −$39.0M | −$24.1M | −$30.9M | −$24.6M |
| Total assets | $563.8M | $331.0M | $180.7M | $26.5M | $35.6M | $65.0M |
| Total liabilities | $113.7M | $85.9M | $23.2M | $16.1M | $17.8M | $19.4M |
| Equity | $450.1M | $245.1M | $157.5M | $10.3M | $17.8M | $45.5M |
| EPS (diluted) | $0.39 | $-4.38 | $-2.36 | $-2.87 | $-5.81 | — |
| Shares out. | 45.9M | 32.5M | 8.2M | 80.1M | 79.7M | 44.7M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- 4.9%
- Net margin
- 11.0%
- Return on equity
- 4.6%
- Return on assets
- 3.7%
- Return on capital (ROCE)
- 1.9%
- Liabilities / assets
- 20.2%
- Debt / equity
- 0.25×
- Book value / share
- $9.82
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- 5.20safe
- Accruals / assets
- −4.6%clean
- Piotroski F-Score
- 5/7mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 5 good- Operating margin is positive
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
- Altman Z″ in the safe zone
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Clinical trials
ClinicalTrials.gov · ongoing · next readout firstInterventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Avoro Capital Advisors LlcPassive (13G)May 15, 2026
- Wellington Management Group LlpPassive (13G)May 15, 2026
- Price T Rowe Associates Inc /Md/Passive (13G)May 15, 2026
- State Street CorpPassive (13G)May 12, 2026
- Janus Henderson Group PlcPassive (13G)May 7, 2026
- Fmr LlcPassive (13G)May 7, 2026
- Blackrock, Inc.Passive (13G)Apr 24, 2026
- Vanguard Group IncPassive (13G)Mar 27, 2026
- Vivo Opportunity Fund Holdings, L.P.Passive (13G)Nov 14, 2025
- Adage Capital Management, L.P.Passive (13G)Nov 13, 2025
- Nantahala Capital Management, LlcPassive (13G)Aug 14, 2025
- Adage Capital Partners Gp, L.L.C.Passive (13G)Feb 12, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 4.4M | 2.3 | -32.5% |
| Apr 30, 2026 | 6.5M | 2.9 | +12.5% |
| Apr 15, 2026 | 5.8M | 1.0 | -31.4% |
| Mar 31, 2026 | 8.5M | 5.4 | -9.4% |
| Mar 13, 2026 | 9.3M | 5.5 | +5.2% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Terminated a material agreement · Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylawsMay 18, 2026
- Other material eventApr 7, 2026
- Entered a material agreement · Regulation FD disclosureApr 6, 2026
- Amended charter or bylawsMar 16, 2026
- Director / officer change · Other material eventFeb 26, 2026
- Results of operationsFeb 25, 2026
- Director / officer changeJan 23, 2026
- Results of operationsJan 12, 2026
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.